Can These Biotech Stocks Remedy Your Portfolio? – RARE, LXRX, ESPR, and INSM

NEW YORK, NY / ACCESSWIRE / March 1, 2016 / Read this right now if you want to see a stock that we think will 10 Bag!!

There is no better time to buy value than right now as smart moneymakers are raising cash to buy value plays on dips, near bottom. Volatility creates opportunity and right now we have identified our Top Pick in Biotech Industry as a winning opportunity. In our top group of Biotech and Healthcare stocks we consider this one gem as our best trade idea right now. Click here for the full details on how to make money from this winner:

http://valuableinvestment.com

The Healthcare sector continues to face a lot of headwinds, but despite the challenges, we see potential in select stocks in this space. Our Stock for this quarter is been followed by a number of our members and like for the past ten years they are eager to see the same successes. After all, finding the great stock ideas for you is our mission. So, if you want to know which name to bank on, join our community of investors today by signing up for free at:

http://valuableinvestment.com

For today, we have issued trade alerts on these four Biotech companies: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Esperion Therapeutics Inc. (NASDAQ: ESPR), and Insmed Inc. (NASDAQ: INSM). Access the full story on these stocks by clicking the link below:

http://valuableinvestment.com/real-story

Now on to our features:

Ultragenyx Pharmaceutical Inc.’s stock finished Monday’s session at $60.99, a slight correction of 2.10% from its previous close. A total of 866,729 shares were traded which was above its three months average volume of 617,560 shares. The Company’s shares are trading below their 50-day moving average by 23.09%. Furthermore, Ultragenyx Pharmaceutical’s stock has a Relative Strength Index (RSI) of 40.32. Do not lose out on any RARE’s trade by activating your free access to the trade alerts now at:

http://valuableinvestment.com/RARE

On Monday, shares in Lexicon Pharmaceuticals Inc. ended the session 2.98% higher at $9.34. The stock recorded a trading volume of 1.13 million shares, which was above its three months average volume of 609,630 shares. The Company is trading 13.05% below its 50-day moving average. Moreover, shares of Lexicon Pharmaceuticals have an RSI of 45.84. Sign up for your trade alert on LXRX at:

http://valuableinvestment.com/LXRX

Esperion Therapeutics Inc.’s stock closed the day at $14.89, down 4.18%. The stock recorded a trading volume of 574,922 shares. The Company’s shares have gained 7.05% in the last one month. The Company is trading 16.09% below its 50-day moving average. Additionally, Esperion Therapeutics’ shares have an RSI of 42.49. Register for free on ValuableInvestment.com and activate your trade alert on ESPR at:

http://valuableinvestment.com/ESPR

On Monday, shares in Insmed Inc. recorded a trading volume of 759,872 shares, higher than their three months average volume of 487,610 shares. The stock ended the day 1.07% higher at $12.23. The Company is trading below its 50-day moving average by 17.35%. Furthermore, shares of Insmed have an RSI of 37.89. Trade Alert on INSM is available for free at:

http://valuableinvestment.com/INSM

--

About ValuableInvestment.com:

Valuable Investment was founded in 2006 and has been successfully alerting investors and shareholders of the most profitable ways to earn a living on Wall Street. A decade is a very long time so we must be doing something right. We encourage everyone to come and try our strategy and see how we have been changing the foundation of research for years.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the “Production Team”) in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY

ValuableInvestment.com, the Author, the Reviewer, and the Sponsor (collectively referred to as the “Publishers”) are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither valuableinvestment.com nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://valuableinvestment.com

RESTRICTIONS

ValuableInvestment.com is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

E-mail: press@valuableinvestment.com

SOURCE: ValuableInvestment.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.